Skip to main content
Neurogene Inc. logo

Neurogene Inc. — Investor Relations & Filings

Ticker · NGNE ISIN · US64135M1053 LEI · 529900A7VIY892SZVW73 US Manufacturing
Open in API
Filings indexed 716 across all filing types
Latest filing 2026-06-08 Regulatory Filings
Country US United States of America
Listing US NGNE

About Neurogene Inc.

https://www.neurogene.com/

Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare and devastating neurological diseases. The company utilizes its proprietary EXACT gene therapy platform, which is designed to deliver therapeutic transgenes with controlled expression to improve safety and efficacy over conventional gene therapies. Its lead product candidate, NGN-401, is in clinical development for the treatment of Rett syndrome. The company is also advancing a gene therapy program for CLN5 Batten disease. Neurogene operates its own GMP manufacturing facility to support its clinical programs.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 92% confidence The document is a Form 8-K “Current Report” filed under the Securities Exchange Act. It reports a Regulation FD disclosure and furnishes a press release and a corporate presentation as Exhibits. It does not contain financial statements as a standalone report, nor is it an earnings release, proxy, or annual/interim report. This is a routine regulatory filing that doesn’t fit other specific categories, making it a Regulatory Filings (RNS) submission.
2026-06-08 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report under Item 5.07 “Submission of Matters to a Vote of Security Holders.” It provides the final voting results from the company’s 2026 Annual Meeting of Stockholders, including votes for director elections, advisory votes on executive compensation, auditor ratification, and frequency of advisory votes. This matches the category for Declaration of Voting Results & Voting Rights Announcements.
2026-06-04 English
8-K - Neurogene Inc. (0001404644) (Filer)
Regulatory Filings Classification · 88% confidence The document is a United States SEC Form 8-K current report, disclosing the furnishing of an earnings press release and corporate presentation as exhibits. It does not itself contain the full financial statements or the underlying press release text, but rather is a regulatory filing serving to announce and furnish those exhibits. There is no substantive financial data presented directly in this text. Therefore, it is best classified under the general regulatory filings fallback category (RNS).
2026-05-12 English
8-K - Neurogene Inc. (0001404644) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 20, 2026. It reports the appointment of a new director to the Board of Directors and the appointment of a Chief Commercial Officer. The key content is about changes in the company's board and senior management. There are no financial statements or detailed financial data presented. The document is not an annual or quarterly report, nor an earnings release. It is not a proxy statement or voting results announcement. The primary focus is on management changes, specifically the expansion of the Board and appointment of a director. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (6620 characters) supports it being a full report rather than a brief announcement or certification. Confidence is high given the clear content and form type.
2026-04-20 English
ARS - Neurogene Inc. (0001404644) (Filer)
Annual Report
2026-04-16 English
DEF 14A - Neurogene Inc. (0001404644) (Filer)
Proxy Solicitation & Information Statement
2026-04-16 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.